TABLE 1.
Patients' baseline features
| Parameters | Statin users (n=) | Nonstatin users (n=) |
|---|---|---|
| Age, years [median (range)] | 71 (48‐93) | 70 (46‐90) |
| Sex | ||
| Male | 60 | 46 |
| Female | 28 | 28 |
| Smoking habit | ||
| Current‐former | 72 | 66 |
| Never | 16 | 8 |
| Performance status | ||
| 0–1 | 80 | 62 |
| 2 | 8 | 12 |
| Histology | ||
| NSqNSCLC | 47 | 45 |
| SqNSCLC | 39 | 22 |
| Other histology | 2 | 7 |
| PDL1 (%) | ||
| 0 | 11 | 17 |
| 1%–49% | 5 | 8 |
| ≥50% | 44 | 26 |
| Not available/Not tested | 28 | 23 |
| IT line of treatment n. | ||
| 1 | 40 | 24 |
| 2 | 48 | 50 |
| Drugs | ||
| Pembrolizumab | 45 | 30 |
| Nivolumab | 34 | 30 |
| Atezolizumab | 9 | 14 |
Abbreviations: IT, Immunotherapy; NSCLC, Nonsmall cell lung cancer; NSq, Nonsquamous; PDL1, Programmed death‐ligand 1; Sq, Squamous.